HOME > TOP STORIES

TOP STORIES

REGULATORY Public-Private Council Will Meet This Summer: Japan PM

April 8, 2025
REGULATORY Diet Begins Deliberations on Amendment of PMD Act, Bill to Repeal Off-Year Scheme

April 7, 2025
BUSINESS Jump in New Grad Hires Seen with Drug Makers in Japan: 2025 Poll

April 4, 2025
REGULATORY Japan Mulls Amendment of GCP Ordinance, Making Single IRBs a Rule

April 3, 2025
REGULATORY Japan Picks 14 “Loss” Products as Drugs with Highest Priority for Development

April 2, 2025
ORGANIZATION JPMA Renews Call for Social Security Not Reliant on Drug Price Cuts: FY2025 Policy

April 2, 2025
COMMENTARY How Will Japan Deal with Expected Cost Spike with Japan-Made Antibiotic APIs?

April 1, 2025
REGULATORY Japan Jittery over Mass Layoffs at FDA, though HHS Says Reviewers Won’t Be Affected

March 31, 2025
REGULATORY Japan Approves J&J’s Lazcluze, Genmab’s Tivdak, and More

March 28, 2025
BUSINESS Kyushu University Offshoot Eyes US Nod for Repositioned ROP Drug Candidate

March 27, 2025
BUSINESS J&J Submits Information Disclosure Requests to Japan Govt over Off-Year Revision

March 26, 2025
BUSINESS FRONTEO’s AI Engine Can Help Unearth Drug Targets, Predict Odds of Success: CTO

March 25, 2025
COMMENTARY Fair or Unfair? PMP Return Applied for First Time in Off-Year Revision

March 24, 2025
BUSINESS New BMS Japan Chief Vows Bold Resource Allocation towards Doubling of Sales

March 21, 2025
BUSINESS Datroway, Zeposia, and More Meds Now Available in Japan; Zepbound Launch Set for April 11

March 21, 2025
REGULATORY US Chamber Raises Japan’s Pharma Policy as Unfair Trade Practice, Prods Federal Govt for Action

March 19, 2025
BUSINESS Novartis CEO Touts Plan to Amp Up Japan Investment, Add 50 Jobs for Early Trials

March 18, 2025
BUSINESS Jiho Survey Finds Improvement in Price Revision Rates for Generic Players

March 17, 2025
BUSINESS KalVista Eyes Japan Debut with World’s 1st Oral On-Demand HAE Drug

March 14, 2025
REGULATORY MHLW Panel OKs List of “High-Priority” Vaccines, including Norovirus Jabs

March 14, 2025

ページ

Chuikyo Debate on FY2026 Drug Pricing Reform

MHLW Floats Deducting Private-Practice Use for Re-Pricing, but Off-Cycle Cuts Possible; GLP-1 Eyed?

Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…

COMMENTARY

FY2026 Reform Debate for Drug Pricing Nears the Finish Line, Balance Needed

By Takashi Ebisawa

Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…

COLUMN

AI in HR: Navigating the Ethical Minefield

By Philip Carrigan

Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…